Advertisement
Advertisement
U.S. Markets open in 7 hrs 7 mins
Advertisement
Advertisement
Advertisement
Advertisement

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2900+0.1800 (+5.79%)
At close: 04:00PM EDT
3.3000 +0.01 (+0.30%)
After hours: 07:34PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1100
Open3.1400
Bid0.0000 x 900
Ask0.0000 x 800
Day's Range3.0150 - 3.3700
52 Week Range2.4200 - 29.0000
Volume477,364
Avg. Volume4,297,487
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into a distribution agreement to market Monkeypox Virus Real-Time PCR Detection Kits with Cosmos Holdings Inc. (Nasdaq: COSM) ("Cosmos"), an international healthcare group headquartered in the United States and with subsidiaries in Greece and the United Kingdom. Pursuant to the agreement

  • PR Newswire

    Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit

    Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkey

  • Benzinga

    EXCLUSIVE: Newly Listed Virax Biolabs Launches Monkeypox Antigen Rapid Test

    Virax Biolabs Group Ltd (NASDAQ: VRAX) has announced the distribution of a Monkeypox Antigen Rapid Test Kit launched in the European markets accepting the CE mark. The specialized diagnostic kits can be found by contacting the company’s sales representatives. Founded in 2013, in July 2022, Virax Biolabs concluded its initial public offering of 1.35 million shares at $5.00 per share, for total gross proceeds of $6.75 million. The test kits are for use in point-of-care settings. They can help heal

Advertisement
Advertisement